| Identification | More | [Name]
Benzhydrylpiperazine | [CAS]
841-77-0 | [Synonyms]
1-BENZHYDRYLPIPERAZINE
1-BENZYHYDRYLPIPERAZINE
1-(DIPHENYLMETHYL)PIPERAZINE
AKOS BBS-00003601
AKOS NCG1-0108
BENZHYDRYLPIPERAZINE
LABOTEST-BB LT00454383
N-BENZHYDRYLPIPERAZINE
N-BENZYLHYDRYLPIPERAZINE
TIMTEC-BB SBB003136
1-(diphenylmethyl)-piperazin
4-benzhydrylpiperazine
Diphenylmethylpiperazine
N-(Diphenylmethyl)piperazine
norcyclizine
1-Benzhydrylpiperazine 97%
1-Benzhydrylpiperazine ,99% | [EINECS(EC#)]
212-667-7 | [Molecular Formula]
C17H20N2 | [MDL Number]
MFCD00038379 | [Molecular Weight]
252.35 | [MOL File]
841-77-0.mol |
| Chemical Properties | Back Directory | [Appearance]
white to light yellow crystalline powder | [Melting point ]
90-93 °C | [Boiling point ]
185°C/2mmHg(lit.) | [density ]
1.0546 (rough estimate) | [vapor pressure ]
0.001Pa at 20℃ | [refractive index ]
1.5794 (estimate) | [Fp ]
115 °C
| [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [solubility ]
Methanol (Slightly) | [form ]
Crystalline Powder | [pka]
9.05±0.10(Predicted) | [color ]
White to light yellow | [Water Solubility ]
0.45 g/L (20 ºC) | [Sensitive ]
Air Sensitive | [Detection Methods]
NMR | [BRN ]
222773 | [LogP]
0.6 at 20℃ | [CAS DataBase Reference]
841-77-0(CAS DataBase Reference) | [NIST Chemistry Reference]
Benzhydryl piperazine(841-77-0) | [Storage Precautions]
Air sensitive |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [RTECS ]
TL6465000
| [F ]
34 | [Hazard Note ]
Irritant | [HazardClass ]
IRRITANT | [HS Code ]
29339900 |
| Hazard Information | Back Directory | [Chemical Properties]
white to light yellow crystalline powder | [Uses]
1-(Diphenylmethyl)piperazine [N-(Diphenylmethyl)piperazine] may be used for the synthesis of 2-nitro-3,4,4-trichloro-1-(propylthio)-1-[4-(diphenylmethyl)piperazin-1-yl]-1,3-butadiene and 2-nitro-3,4,4-trichloro-1-(octadecylthio)-1-[4-(diphenylmethyl)piperazin-1-yl]-1,3-butadiene. | [Uses]
1-Benzhydrylpiperazine is an intermediate used in drug synthesis
| [Uses]
Cinnarizine (C465300) impurity. | [Synthesis Reference(s)]
Journal of the American Chemical Society, 77, p. 1098, 1955 DOI: 10.1021/ja01610a006 | [General Description]
1-(Diphenylmethyl)piperazine is an intermediate during drug synthesis. It has been reported to be formed during the oxidative metabolism of cinnarizine (CZ) [1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine] in rat liver microsomes. It reacts with quinone in acetonitrile, followed by oxidation with an alkaline potassium ferricyanide, to afford 4-amino-3,6-di(tert-butyl)-o-benzoquinones. | [Flammability and Explosibility]
Notclassified | [Synthesis]
General procedure for the synthesis of N-diphenylmethylpiperazine from piperazine and diphenylmethyl bromide: accurately weigh diphenylmethyl bromide (10 g, 41 mmol), piperazine (9 g, 105 mmol), potassium carbonate (K2CO3, 14 g, 101 mmol) and sodium iodide (NaI). Piperazine (6 g, 40 mmol) was dissolved in toluene (85 mL) and stirred until completely dissolved. The reaction mixture was placed in an oil bath at 110°C and refluxed for 4 hours. The progress of the reaction was monitored by thin layer chromatography (TLC) during the reaction. After completion of the reaction, it was cooled to room temperature and dichloromethane (DCM) was added to disperse the reaction mixture. The insoluble material was removed by filtration and the filtrate was collected. The filtrate was concentrated and purified by silica gel column chromatography using an elution system containing 1% triethylamine in a gradient elution with petroleum ether and ethyl acetate (ratio tapered from 1:2 to 1:3). The target compound N-diphenylmethylpiperazine (S8, 7.6 g) was finally obtained in 74.2% yield. | [References]
[1] Patent: CN103524413, 2016, B. Location in patent: Paragraph 0060; 0061; 0062; 0066
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 4, p. 833 - 844
[3] European Journal of Medicinal Chemistry, 1987, vol. 22, p. 243 - 250
[4] Patent: US4355031, 1982, A |
|
|